The urgent need to recover MHC class I in cancers for effective immunotherapy

Garrido, Federico; Aptsiauri, Natalia; Doorduijn, Elien M.; García‐Lora, Ángel M.; Hall, Thorbald van

doi:10.1016/j.coi.2015.12.007

reviewCurrent Opinion in ImmunologyJan 18, 2016HYBRID OA

The urgent need to recover MHC class I in cancers for effective immunotherapy

FGFederico Garrido NANatalia Aptsiauri EMElien M. Doorduijn ÁMÁngel M. García‐Lora TVThorbald van Hall

Instituto de Investigación Biosanitaria de Granada · Hospital Universitario Virgen de las Nieves · +2 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Immune escape strategies aimed to avoid T-cell recognition, including the loss of tumor MHC class I expression, are commonly found in malignant cells. Tumor immune escape has proven to have a negative effect on the clinical outcome of cancer immunotherapy, including treatment with antibodies blocking immune checkpoint molecules. Hence, there is an urgent need to develop novel approaches to overcome tumor immune evasion. MHC class I antigen presentation is often affected in human cancers and the capacity to induce upregulation of MHC class I cell surface expression is a critical step in the induction of tumor rejection. This review focuses on characterization of rejection, escape, and dormant profiles of tumors…

Citation impact

561

total citations

FWCI: 26.15
Percentile: 100%
References: 76

Citations per year

Authors

5

Topics & keywords

Topics

Keywords

Immunotherapy
MHC class I
Major histocompatibility complex
Class (philosophy)
Immunology
MHC class II
Cancer immunotherapy
Medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.